JAK1 and Alzheimer disease: Upadacitinib, a selective and reversible oral small-molecule drug that inhibits JAK1, has been approved by the European Medicines Agency and the U.S. Food and Drug Administration (FDA) for usage in patients with moderate-to-severe AD aged 12 years and above.